Shuwen Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuwen Yu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Lu Wang
Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University
6 shared publications Min Jiang
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
3 shared publications- Mingliang Zhu
Department of Pharmacy The Affiliated Hospital of Shandong University of Traditional Chinese Medicine Jinan Shandong China
3 shared publications Kewei Yu
Department of Pharmacy, Jinan Central Hospital Affiliated to Shandong University, Jinan, China
2 shared publicationsLu Wang
Department of Pharmacy, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
2 shared publicationsHuan-Hua Luo
Department of Pharmacy, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 35
Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in ApcMin/+ mice
Introduction: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) regulates lipoprotein homeostasis in humans. Evolocumab is a selective PCSK9 inhibitor that can reduce low-density lipoprotein cholesterol (LDLC) level and decrease hypercholesterolemia. The current study aimed to explore whether PCSK9 increases the risk of colorectal cancer. Methods: First, we utilized the classic intestinal tumor ApcMin/+ mouse model and PCSK9 knock-in (KI) mice to establish ApcMin/+PCSK9(KI) mice. Then, we investigated the effect of PCSK9 overexpression in ApcMin/+PCSK9(KI) mice and PCSK9 inhibition using evolocumab on the progression of intestinal tumors in vivo by hematoxylin and eosin (HE) staining, Western blot, and immunohistochemistry (IHC) assay. Results: ApcMin/+PCSK9(KI) mice had higher numbers and larger sizes of adenomas, with 83.3% of these mice developing adenocarcinoma (vs. 16.7% of ApcMin/+ mice). However, treatment with evolocumab reduced the number and size of adenomas and prevented the development of adenocarcinomas in ApcMin/+ mice. PCSK9 overexpression reduced tumor cell apoptosis, the Bax/bcl-2 ratio, and the levels of cytokine signaling 3 protein (SOCS3) suppressors, but activated Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling in intestinal tumors. In contrast, evolocumab treatment had the opposite effect on ApcMin/+mice. Conclusion: PCSK9 might act as an oncogene or have an oncogenic role in the development and progression of colorectal cancer in vivo via activation of JAK2/STAT3/SOCS3 signaling.
- 1 January 2021
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 35
Open AccessPro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in ApcMin/+ mice
Introduction: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) regulates lipoprotein homeostasis in humans. Evolocumab is a selective PCSK9 inhibitor that can reduce low-density lipoprotein cholesterol (LDLC) level and decrease hypercholesterolemia. The current study aimed to explore whether PCSK9 increases the risk of colorectal cancer. Methods: First, we utilized the classic intestinal tumor ApcMin/+ mouse model and PCSK9 knock-in (KI) mice to establish ApcMin/+PCSK9(KI) mice. Then, we investigated the effect of PCSK9 overexpression in ApcMin/+PCSK9(KI) mice and PCSK9 inhibition using evolocumab on the progression of intestinal tumors in vivo by hematoxylin and eosin (HE) staining, Western blot, and immunohistochemistry (IHC) assay. Results: ApcMin/+PCSK9(KI) mice had higher numbers and larger sizes of adenomas, with 83.3% of these mice developing adenocarcinoma (vs. 16.7% of ApcMin/+ mice). However, treatment with evolocumab reduced the number and size of adenomas and prevented the development of adenocarcinomas in ApcMin/+ mice. PCSK9 overexpression reduced tumor cell apoptosis, the Bax/bcl-2 ratio, and the levels of cytokine signaling 3 protein (SOCS3) suppressors, but activated Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling in intestinal tumors. In contrast, evolocumab treatment had the opposite effect on ApcMin/+mice. Conclusion: PCSK9 might act as an oncogene or have an oncogenic role in the development and progression of colorectal cancer in vivo via activation of JAK2/STAT3/SOCS3 signaling.
- Open Access
- 1 September 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 129, 110389
Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement
- 1 September 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 129, 110389
Open AccessCombined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement
- Open Access
- 6 July 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-9
Myricetin induces apoptosis and autophagy by inhibiting PI3K/Akt/mTOR signalling in human colon cancer cells
Background: The compound 3,3′,4′,5,5′,7-hexahydroxyflavone (myricetin) is a natural flavonoid with antitumour activity. Most of the studies on myricetin have focused on the induction of tumour cell apoptosis, and little is known about the regulatory effects of myricetin on autophagy in colorectal cancer. Methods: Here, we studied the effects of myricetin on colon cancer cell proliferation, apoptosis and autophagy. We detected colon cancer cell apoptosis induced by myricetin via flow cytometry and Hoechst 33258 staining. Transmission electron microscopy was performed to observe the morphological changes associated with autophagy. The expression levels of apoptosis-, autophagy- and PI3K/Akt/mTOR signalling-related proteins were measured by Western blot analysis. Results: This study confirmed that myricetin inhibits the proliferation of 4 kinds of colon cancer cell lines. Myricetin induced cell apoptosis and autophagy by inhibiting PI3K/Akt/mTOR signalling pathway. In addition, the inhibition of autophagy with 3-methyladenine (3-MA) promoted the apoptosis of myricetin-treated colon cancer cells. Conclusions: Considering that myricetin induces apoptosis and autophagy in colon cancer cells, myricetin may become a viable candidate for chemotherapy; it could be used to exert tumour inhibitory effects alone or as adjuvant chemotherapy to inhibit autophagy. These studies may provide further evidence for the potential use of myricetin in the treatment of colon cancer.
- 6 July 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-9
Open AccessMyricetin induces apoptosis and autophagy by inhibiting PI3K/Akt/mTOR signalling in human colon cancer cells
Background: The compound 3,3′,4′,5,5′,7-hexahydroxyflavone (myricetin) is a natural flavonoid with antitumour activity. Most of the studies on myricetin have focused on the induction of tumour cell apoptosis, and little is known about the regulatory effects of myricetin on autophagy in colorectal cancer. Methods: Here, we studied the effects of myricetin on colon cancer cell proliferation, apoptosis and autophagy. We detected colon cancer cell apoptosis induced by myricetin via flow cytometry and Hoechst 33258 staining. Transmission electron microscopy was performed to observe the morphological changes associated with autophagy. The expression levels of apoptosis-, autophagy- and PI3K/Akt/mTOR signalling-related proteins were measured by Western blot analysis. Results: This study confirmed that myricetin inhibits the proliferation of 4 kinds of colon cancer cell lines. Myricetin induced cell apoptosis and autophagy by inhibiting PI3K/Akt/mTOR signalling pathway. In addition, the inhibition of autophagy with 3-methyladenine (3-MA) promoted the apoptosis of myricetin-treated colon cancer cells. Conclusions: Considering that myricetin induces apoptosis and autophagy in colon cancer cells, myricetin may become a viable candidate for chemotherapy; it could be used to exert tumour inhibitory effects alone or as adjuvant chemotherapy to inhibit autophagy. These studies may provide further evidence for the potential use of myricetin in the treatment of colon cancer.
- Open Access
- 1 December 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 120, 109506
Anti-tumor effects and associated molecular mechanisms of myricetin
- 1 December 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 120, 109506
Open AccessAnti-tumor effects and associated molecular mechanisms of myricetin
- Open Access
- 22 March 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (6) , 1943-1954
Immunoglobulin‑like transcript 4 and human leukocyte antigen‑G interaction promotes the progression of human colorectal cancer
Immunoglobulin‑like transcript (ILT) 4, a negative regulator of immune response in allograft rejection, autoimmunity and infectious diseases, has recently been determined to serve important roles in tumor development. In the present study, the co‑expression of ILT4 and human leukocyte antigen‑G (HLA‑G) in tissues of human primary colorectal cancer (CRC) was revealed, and its association with older age, advanced stage, regional lymph node involvement and poor overall survival time was identified. In CRC cell lines, ILT4 and HLA‑G co‑expression and their autocrine regulation was demonstrated. ILT4 interference affected HLA‑G expression and regulated the cell proliferation, invasion and migration of CRC. HLA‑G fusion protein treatment also increased ILT4 expression in a dose‑dependent manner, thereby activating protein kinase B (AKT) and extracellular signal‑regulated kinase (ERK) signaling, and facilitating the proliferation, migration and invasion of CRC cells. Additionally, the AKT and ERK activation, and CRC cell malignant characteristics induced by HLA‑G may be suppressed by blocking ILT4. The present results indicated that the interaction of ILT4 and its ligand HLA‑G promotes CRC progression through AKT and ERK signal activation, providing a novel strategy of blocking ILT4/HLA‑G for the treatment of CRC.
- 22 March 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (6) , 1943-1954
Open AccessImmunoglobulin‑like transcript 4 and human leukocyte antigen‑G interaction promotes the progression of human colorectal cancer
Immunoglobulin‑like transcript (ILT) 4, a negative regulator of immune response in allograft rejection, autoimmunity and infectious diseases, has recently been determined to serve important roles in tumor development. In the present study, the co‑expression of ILT4 and human leukocyte antigen‑G (HLA‑G) in tissues of human primary colorectal cancer (CRC) was revealed, and its association with older age, advanced stage, regional lymph node involvement and poor overall survival time was identified. In CRC cell lines, ILT4 and HLA‑G co‑expression and their autocrine regulation was demonstrated. ILT4 interference affected HLA‑G expression and regulated the cell proliferation, invasion and migration of CRC. HLA‑G fusion protein treatment also increased ILT4 expression in a dose‑dependent manner, thereby activating protein kinase B (AKT) and extracellular signal‑regulated kinase (ERK) signaling, and facilitating the proliferation, migration and invasion of CRC cells. Additionally, the AKT and ERK activation, and CRC cell malignant characteristics induced by HLA‑G may be suppressed by blocking ILT4. The present results indicated that the interaction of ILT4 and its ligand HLA‑G promotes CRC progression through AKT and ERK signal activation, providing a novel strategy of blocking ILT4/HLA‑G for the treatment of CRC.
- Open Access
- 1 December 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 108, 600-609
Dual gene deficient models of ApcMin/+ mouse in assessing molecular mechanisms of intestinal carcinogenesis
- 1 December 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 108, 600-609
Open AccessDual gene deficient models of ApcMin/+ mouse in assessing molecular mechanisms of intestinal carcinogenesis
- 1 November 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 107, 177-184
Dual functional roles of the MyD88 signaling in colorectal cancer development
- 1 November 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 107, 177-184
Dual functional roles of the MyD88 signaling in colorectal cancer development
- 1 July 2018
- Vol. 73 (7) , 363-368
Contribution of drugs acting on the TLRs/MyD88 signaling pathway on colitis-associated cancer
Toll-like receptors play a particularly significant role in colitis-associated cancer (CAC). MyD88 is the mediator in TLRs signal transduction process and it is indispensable for TLRs signaling except for TLR3. The conclusion of studies about the role of TLRs/MyD88 signaling in colon cancer remains contradictory: on one hand, TLRs/MyD88 signaling contributes to colon tumor cell proliferation, invasion and metastasis and inhibition of the expression of TLRs or MyD88 could prevent the growth of colon cancer cells; on the other hand, activation of the TLRs/MyD88 signaling pathway could inhibit the proliferation of colon cancer cells. This article is based on the expression levels of TLRs or MyD88 and the activation degrees of TLRs/MyD88 signaling pathway in different periods of colon cancer and, reviews the roles of TLRs/MyD88 signaling in the tumorigenesis and procession of CAC and the clinical application of agonists and inhibitor of TLRs or MyD88. This article is intended to explore the diverse roles of TLRs/MyD88 signaling pathway in CAC and to reveal the related molecular mechanism.
- 1 July 2018
- Vol. 73 (7) , 363-368
Contribution of drugs acting on the TLRs/MyD88 signaling pathway on colitis-associated cancer
Toll-like receptors play a particularly significant role in colitis-associated cancer (CAC). MyD88 is the mediator in TLRs signal transduction process and it is indispensable for TLRs signaling except for TLR3. The conclusion of studies about the role of TLRs/MyD88 signaling in colon cancer remains contradictory: on one hand, TLRs/MyD88 signaling contributes to colon tumor cell proliferation, invasion and metastasis and inhibition of the expression of TLRs or MyD88 could prevent the growth of colon cancer cells; on the other hand, activation of the TLRs/MyD88 signaling pathway could inhibit the proliferation of colon cancer cells. This article is based on the expression levels of TLRs or MyD88 and the activation degrees of TLRs/MyD88 signaling pathway in different periods of colon cancer and, reviews the roles of TLRs/MyD88 signaling in the tumorigenesis and procession of CAC and the clinical application of agonists and inhibitor of TLRs or MyD88. This article is intended to explore the diverse roles of TLRs/MyD88 signaling pathway in CAC and to reveal the related molecular mechanism.